Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

Deere’s Strategic Acquisition Meets Analyst Caution

Andreas Sommer by Andreas Sommer
December 22, 2025
in Analysis, Earnings, Industrial, Mergers & Acquisitions
0
Deere Stock
0
SHARES
25
VIEWS
Share on FacebookShare on Twitter

Deere & Company announced today that it has finalized an agreement to acquire Tenna, a move that coincides with a period of significant earnings estimate revisions and mixed signals from major shareholders. The central question for investors is whether this strategic purchase can offset near-term profitability concerns.

Financial Performance and Revised Forecasts

The company’s recent operational results showed strength in revenue but a slight earnings miss. For the third quarter of 2025, Deere reported earnings per share of $3.93, narrowly below the $3.96 consensus expectation. Revenue, however, came in at $12.39 billion, marking a solid 14.1% year-over-year increase.

This operational backdrop is now shadowed by substantial downward revisions from analysts. Zacks Research made significant cuts to its estimates last week:
* First Quarter 2026 EPS: Reduced from $2.83 to $1.99.
* Full Year 2026 EPS: Lowered from $18.83 to $16.74.
* Full Year 2027 EPS: Cut from $24.20 to $21.55.

Despite these revisions, the consensus analyst rating remains a “Moderate Buy,” with an average price target of $522.70. A note of divergence comes from JPMorgan, which downgraded its stance to “Neutral” and set a lower price target of $460. This split highlights differing views on the company’s profit trajectory following the estimate adjustments.

The Tenna Acquisition and Institutional Activity

The acquisition of Tenna aligns with ongoing consolidation within the agricultural technology sector. Deere has not disclosed the financial terms of the deal, leaving the timeline for any tangible revenue or earnings contribution unclear. In the short term, the lowered profit expectations appear more impactful than the acquisition announcement, which is unlikely to fully counterbalance the immediate forecast reductions.

Should investors sell immediately? Or is it worth buying Deere?

Major institutional investors have shown a divided response:
* Voya Investment Management slashed its stake by 72.1%, selling 565,643 shares.
* Sarasin & Partners reduced its holding by 13,638 shares, a decrease of 3.4%.
* Conversely, Exchange Traded Concepts boosted its position by 118.5%, and Wedge Capital increased its holdings by 28%. Several other asset managers initiated new positions or added moderately.

Insider Transactions and Shareholder Returns

Adding to the nuanced picture, CEO John C. May II sold 11,106 shares in late November, a transaction valued at approximately $5.55 million. This sale decreased his direct holdings by about 8.99%. While such insider sales often attract scrutiny, they are not necessarily indicative of the company’s operational outlook.

For income-focused investors, Deere maintains a quarterly dividend payout of $1.62 per share. Annualized, this equates to $6.48, yielding roughly 1.4% at current share prices.

Outlook and Key Considerations

The Tenna deal bolsters Deere’s long-term strategic positioning but does not yet provide quantifiable benefits to its financials. The immediate landscape is shaped by the sharp downward revisions to earnings forecasts and selective selling by some large investors. Moving forward, the market will be watching for Deere to provide detailed integration plans or updated financial guidance. Clear communication on these fronts may be necessary to reconcile the current divergences in analyst opinions and institutional investor positioning.

Ad

Deere Stock: Buy or Sell?! New Deere Analysis from February 7 delivers the answer:

The latest Deere figures speak for themselves: Urgent action needed for Deere investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 7.

Deere: Buy or sell? Read more here...

Tags: Deere
Andreas Sommer

Andreas Sommer

About Andreas Sommer Over 40 years of expertise in market analysis, chart technical analysis, and strategic investment advisory. With more than four decades of experience in banking and financial journalism, Andreas Sommer is recognized as one of the leading analysts in the German-speaking market. His deep understanding of market dynamics and technical analysis has helped countless investors navigate complex financial markets.
Areas of Expertise:
  • Technical Chart Analysis
  • Strategic Investment Advisory
  • Market Trend Analysis
  • Financial Journalism
Andreas brings unparalleled insights from his extensive career in banking and financial markets, making him a trusted voice for investors seeking professional guidance.

Related Posts

Orthofix Medical Stock
Earnings

Orthofix Medical Strengthens Scientific Foundation for Biologics Portfolio

February 7, 2026
CrossFirst Bankshares Stock
Analysis

A New Chapter for First Busey as CrossFirst Merger Finalizes

February 7, 2026
Golden Entertainment Stock
Gaming & Metaverse

Golden Entertainment to Exit Public Markets in Strategic Privatization Deal

February 7, 2026
Next Post
UBS Stock

UBS Shares Face Integration Test Amid Restructuring Moves

Intel Stock

Intel's Strategic Pivot Gains Momentum Amid Market Volatility

Alibaba Stock

Alibaba's Strategic Chip Procurement Fuels AI Ambitions

Recommended

Super Micro Computer Stock

Super Micro Stock Surges Amid AI Infrastructure Boom

4 months ago
Adobe Stock

Adobe’s AI Ambitions Face Investor Skepticism

4 months ago
IBM Stock

Strong IBM Earnings Fail to Impress Market as Key Segment Shows Weakness

4 months ago
Inozyme Pharma Inc Stock

Inozyme Pharma Acquisition Finalized: Strategic Focus Shifts to Clinical Development

5 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Myers Industries Set to Report Full-Year and Q4 2025 Results

OneSpan Strengthens Mobile Security Arsenal with Strategic Acquisition

Riley Exploration Permian Bolsters Board with Industry Veteran Amid Shareholder Activity

Great Lakes Dredge & Dock: A Cash Flow Inflection Point Approaches

Investors Await March Report for Boston Omaha’s Strategic Direction

Universal Insurance Maintains Quarterly Payout Amid Sector Headwinds

Trending

Orthofix Medical Stock
Earnings

Orthofix Medical Strengthens Scientific Foundation for Biologics Portfolio

by Rodolfo Hanigan
February 7, 2026
0

Investor attention turns to Orthofix Medical as the company bolsters the clinical support for its biologics business...

CrossFirst Bankshares Stock

A New Chapter for First Busey as CrossFirst Merger Finalizes

February 7, 2026
Golden Entertainment Stock

Golden Entertainment to Exit Public Markets in Strategic Privatization Deal

February 7, 2026
Myers Industries Stock

Myers Industries Set to Report Full-Year and Q4 2025 Results

February 7, 2026
OneSpan Stock

OneSpan Strengthens Mobile Security Arsenal with Strategic Acquisition

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Orthofix Medical Strengthens Scientific Foundation for Biologics Portfolio
  • A New Chapter for First Busey as CrossFirst Merger Finalizes
  • Golden Entertainment to Exit Public Markets in Strategic Privatization Deal

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com